UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

Incyte (INCY) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

US pharmaceutical giant Eli Lilly has launched its blockbuster diabetes and weight-loss drug, Mounjaro, in India following ...

Glasgow, Scotland Wednesday, March 19, 2025, 09:00 Hrs [IST] ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Scientists have developed a revolutionary AI ‘fingerprint’ technology that can accurately show how cancer cells respond to new drugs, by simply observing changes to their shape. The new technology, ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 with BeiGene ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...